Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis

Liver International

Volumn 31, Issue 9, 2011, Pages 1285-1297

  Svegliati Baroni, Gianluca ^a   Saccomanno, Stefania ^a   Rychlicki, Chiara ^a   Agostinelli, Laura ^a   de Minicis, Samuele ^a   Candelaresi, Cinzia ^a   Faraci, Graziella ^a   Pacetti, Deborah ^a   Vivarelli, Marco ^a   Nicolini, Daniele ^a   Garelli, Paolo ^a   Casini, Alessandro ^b   Manco, Melania ^c   Mingrone, Geltrude ^d   Risaliti, Andrea ^a   Frega, Giuseppe N ^a   Benedetti, Antonio ^a   Gastaldelli, Amalia ^e  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

GLP 1 receptor; Hepatic lipid oxidation; High fat diet; NASH

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GLUCOSE METABOLISM; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN SENSITIVITY; INTRACELLULAR SIGNALING; LIPID DIET; LIPID METABOLISM; LIPID OXIDATION; LIVER BIOPSY; LIVER CELL; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; WESTERN BLOTTING;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BIOPSY; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DIETARY FATS; DISEASE MODELS, ANIMAL; FATTY ACIDS; FATTY LIVER; GENE EXPRESSION REGULATION; HEP G2 CELLS; HEPATOCYTES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIVER; MALE; OXIDATION-REDUCTION; PEPTIDES; PHOSPHORYLATION; PPAR ALPHA; PPAR GAMMA; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCAGON; SIGNAL TRANSDUCTION; TIME FACTORS; VENOMS;

EID: 80052517174     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02462.x     Document Type: Article

References (46)

1. Bugianesi E, Mccullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005; 42: 987-1000.
2. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-50.
3. Gastaldelli A, Cusi K, Pettiti M, et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 2007; 133: 496-506.
4. Holst JJ. Gastric inhibitory polypeptide analogues: do they have a therapeutic role in diabetes mellitus similar to that of glucagon-like peptide-1? BioDrugs 2002; 16: 175-81.
5. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24: 275-86.
6. Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009; 297: 127-36.
7. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-705.
8. Abu-Hamdah R, Rabiee A, Meneilly GS, et al. Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab 2009; 94: 1843-52.
9. Korner M, Stockli M, Waser B, Reubi JC.GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 2007; 48: 736-43.
10. Vahl TP, Tauchi M, Durler TS, et al. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 2007; 148: 4965-73.
11. Gupta NA, Mells J, Dunham RM, et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010; 51: 1584-92.
12. American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1702-4.
13. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
14. Surwit R, Feinglos M, Rodin J, et al. Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice. Metabolism 1995; 44: 645-51.
15. Svegliati-Baroni G, Candelaresi C, Saccomanno S, et al. A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. Am J Pathol 2006; 169: 846-60.
16. Barzilai N, She L, Liu BQ, et al. Surgical removal of visceral fat reverses hepatic insulin resistance. Diabetes 1999; 48: 94-8.
17. Folch J, Lees M, SloaneStanley GH.A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957; 226: 497-509.
18. Svegliati Baroni G, D'ambrosio L, Ferretti G, et al. Fibrogenic effect of oxidative stress on rat hepatic stellate cells. Hepatology 1998; 27: 720-6.
19. Marzioni M, Alpini G, Saccomanno S, et al. Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis. Gastroenterology 2007; 133: 244-55.
20. Bishop-Bailey D, Warner TD. PPAR gamma ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor-gamma antagonist. Faseb J 2003; 17: 1925-7.
21. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-74.
22. Kehrer JP, Biswal SS, La E, et al. Inhibition of peroxisome-proliferator-activated receptor (PPAR) alpha by MK886. Biochem J 2001; 356(Part 3): 899-906.
23. Levy JR, Clore JN, Stevens W. Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats. Hepatology 2004; 39: 608-16.
24. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 2008; 14: 72-81.
25. Kotronen A, Seppala-Lindroos A, Vehkavaara S, et al. Liver fat and lipid oxidation in humans. Liver Int 2009; 29: 1439-46.
26. Ali R, Cusi K. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann Med 2009; 41: 265-78.
27. Mingrone G, Nolfe G, Gissey GC, et al. Circadian rhythms of GIP and GLP1 in glucose-tolerant and in type 2 diabetic patients after biliopancreatic diversion. Diabetologia 2009; 52: 873-81.
28. Ranganath LR, Beety JM, Morgan LM, et al. Attenuated GLP-1 secretion in obesity: cause or consequence? Gut 1996; 38: 916-9.
29. Delgado E, Luque MA, Alcantara A, et al. Glucagon-like peptide-1 binding to rat skeletal muscle. Peptides 1995; 16: 225-9.
30. Valverde I, Merida E, Delgado E, Trapote MA, Villanueva-Penacarrillo ML. Presence and characterization of glucagon-like peptide-1 (7-36) amide receptors in solubilized membranes of rat adipose tissue. Endocrinology 1993; 132: 75-9.
31. Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995; 358: 219-24.
32. Dardevet D, Moore MC, Dicostanzo CA, et al. Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors. Am J Physiol Gastrointest Liver Physiol 2005; 289: G806-14.
33. Ayala JE, Bracy DP, James FD, et al. The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. Endocrinology 2009; 150: 1155-64.
34. D'alessio D, Vahl T, Prigeon R. Effects of glucagon-like peptide 1 on the hepatic glucose metabolism. Horm Metab Res 2004; 36: 837-41.
35. Zheng D, Ionut V, Mooradian V, Stefanovski D, Bergman RN. Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver. Diabetes 2009; 58: 352-9.
36. Lee YS, Shin S, Shigihara T, et al. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. Diabetes 2007; 56: 1671-9.
37. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006; 43: 173-81.
38. Ayala JE, Bracy DP, James F D, et al. Glucagon-like peptide-1 receptor knockout mice are protected from high-fat diet-induced insulin resistance. Endocrinology 2010; 151: 4678-87.
39. Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1343-51.
40. Bugianesi E, Gastaldelli A, Vanni E, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005; 48: 634-42.
41. Cusi K. Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2009; 16: 141-9.
42. Shulman AI, Mangelsdorf DJ. Retinoid x receptor heterodimers in the metabolic syndrome. N Engl J Med 2005; 353: 604-15.
43. Gastaldelli A, Harrison SA, Belfort-Aguilar R, et al. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 2009; 50: 1087-93.
44. Hirasawa A, Tsumaya K, Awaji T, et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 2005; 11: 90-4.
45. Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420: 333-6.
46. Diaz-Delfin J, Morales M, Caelles C. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway. Diabetes 2007; 56: 1865-71.